Question 1

Is Ozempic a GLP-1?

Accepted Answer

Yes, in the sense the question usually means. A 2023 review states that semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. Agonist here means a molecule that turns a receptor on. GLP-1 itself is not a medicine at all. A 2019 review describes glucagon-like peptide-1 (GLP-1) as an incretin hormone with important effects on glycemic control and body weight regulation. Incretin means a gut hormone that prompts the pancreas to put out insulin after a meal. So semaglutide copies a hormone rather than being one. The natural version does not last, and the same review describes efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes. That engineering is the only reason a weekly injection is possible.

Question 2

What is the difference between GLP-1 and semaglutide?

Accepted Answer

GLP-1 names a class and semaglutide names one member of it, which is why the two words keep getting swapped. A 2021 review lists what is in that class: GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide). So no, not every GLP-1 medicine is semaglutide. The same review sorts them by how long each one lasts. Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c. HbA1c is a blood test covering roughly three months of average blood sugar. Within that half of the class the review puts semaglutide at the strong end, noting that more recently developed agents, in particular semaglutide, are characterized by greater efficacy with respect to lowering plasma glucose as well as body weight.

Question 3

Is semaglutide the same as tirzepatide?

Accepted Answer

No, and the structural difference is one receptor. The report of the 2021 diabetes comparison describes semaglutide as a selective GLP-1 receptor agonist, meaning it acts on the single receptor that answers the gut hormone released after a meal. The same report sets tirzepatide out as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, so two receptors where semaglutide has one. That second receptor answers a different gut hormone, and semaglutide does not touch it. Everything else that separates the two comes out of trials rather than out of chemistry. They also reached the clinic by separate routes. A 2022 review records that the SUSTAIN, PIONEER and STEP programmes led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. Tirzepatide ran its own programme, and the amounts on the two labels are not on a shared scale.

Question 4

What did semaglutide do in the trial that compared it with tirzepatide?

Accepted Answer

One trial has put the two side by side in obesity. In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. A total of 751 participants underwent randomization. At week 72 the semaglutide arm recorded a least-squares mean percent change in weight of -13.7%, against -20.2% in the tirzepatide arm. The investigators concluded that treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. Two design features set the limits on that. Open-label means no one was blinded to the assignment. And a maximum tolerated dose means the semaglutide group sat at 1.7 mg or 2.4 mg depending on what each person could take, rather than at one fixed amount.

Question 5

Was semaglutide compared at its highest amount?

Accepted Answer

No, and this is the part most comparisons leave out. The diabetes trial assigned tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg, and a 2021 trial describes semaglutide 1·0 mg as the dose approved for diabetes treatment rather than the amount approved for weight. The obesity comparison went no higher than 2.4 mg. A 2025 trial then took semaglutide further. In adults with obesity over 72 weeks, the mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg, at -18·7% against -15·6%. Nothing among the research behind this page compares 7·2 mg with tirzepatide in the same participants. So the head-to-head record describes the amounts those two trials assigned, rather than the full range semaglutide has since been tested across, and the two claims get merged constantly.

Question 6

Is semaglutide or tirzepatide better?

Accepted Answer

We do not rank compounds, and here the published record makes that refusal easy to explain rather than evasive. The obesity figures are in the section above. In the diabetes trial the investigators concluded that in patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. What neither trial establishes is what any one reader would get, at what amount, for how long, and at what cost in side effects. A larger group average and a better outcome for one person are not the same finding, and only the first of them has been measured. The investigators framed their own question narrowly. The 2025 report opens by stating that the efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown, and it closed one comparison, in one population, at one pair of amounts.

Question 7

Which makes you sicker, semaglutide or tirzepatide?

Accepted Answer

One trial counted the digestive events in both groups at the same time. In a phase 1 trial in type 2 diabetes, patients were randomly assigned (3:3:2) to subcutaneously receive either tirzepatide 15 mg, semaglutide 1 mg, or placebo once per week, with 45 in the tirzepatide 15 mg group, 44 in the semaglutide 1 mg group, and 28 in the placebo group. The counts came out close together. The safety profiles of tirzepatide and semaglutide were similar, with gastrointestinal adverse events being the most common, at 11 (24%), 13 (30%), and seven (25%) with nausea across the three groups. Read the group sizes before the percentages. Forty-five people and forty-four people is far too few to separate two rates that sit this close. A trial built to measure insulin secretion cannot settle which compound makes anybody sicker, and no trial we cite was built for that question. Those counts are an observation sitting beside each other rather than a comparison between them.

Question 8

How do you switch from semaglutide to tirzepatide?

Accepted Answer

No trial among the research behind this page has moved anybody from one to the other and measured what happened. There is no interval, no schedule and no reported outcome to pass on, because every trial covered on this page assigned one compound for the whole run. What is on record is how long semaglutide lingers. A 2024 systematic review describes a long t1/2 that allows for once-weekly subcutaneous administration. The term t1/2 means half-life, the time taken for half of a dose to leave the blood. That explains why a weekly injection works and settles nothing about a changeover. A half-life describes how a compound clears, rather than when a person should begin a different one, and the second of those is a clinical decision that no published source covered here makes.

Question 9

Is 2.5 mg of semaglutide the same as 2.5 mg of tirzepatide?

Accepted Answer

No, and nothing among the research behind this page puts the two on one scale. Each was tested at amounts set inside its own programme. Semaglutide was assigned at a dose of 1 mg in the diabetes comparison and at 1.7 mg or 2.4 mg in the obesity comparison, while tirzepatide ran at 5 mg, 10 mg and 15 mg. A 2021 trial records semaglutide 1·0 mg (the dose approved for diabetes treatment), which is a regulatory fact about one compound and says nothing about the other. There is no published conversion between them, and we will not invent one. That matters more than it sounds. The milligram figures sit in different ranges entirely, so reading a number across from one label to the other is not a small error of degree. No study in these sources has validated any step between the two.

Question 10

What happens if you take semaglutide and tirzepatide together?

Accepted Answer

No trial among the research behind this page has assigned both to the same participants, so there is no result, no interaction report and no schedule to describe. Every comparison on this page assigned one compound or the other. What has been tested is a different idea altogether: building a second receptor action into a single molecule. That is what tirzepatide is, described in its own trial report as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, then run through trials of 1,879 and 751 participants. Hold that distinction, because it is the one that gets lost. A second action designed into one molecule has been assigned, counted and published. Stacking two finished injections in the same week has not been assigned to anybody, which makes it unmeasured rather than ruled out.

Question 11

What has semaglutide been combined with in a trial?

Accepted Answer

One pairing has been through phase 3, and it is not with tirzepatide. A 68-week trial tested the combination (known as CagriSema), in which semaglutide at a dose of 2.4 mg is given alongside cagrilintide at a dose of 2.4 mg. A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide-semaglutide. The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo. A second trial ran the same pairing in adults with type 2 diabetes, where the estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group. So the combination that has actually been measured is semaglutide with cagrilintide, in two randomised trials against placebo. Neither was compared with tirzepatide, and a result against placebo cannot stand in for one.

Question 12

Semaglutide vs retatrutide: what is known?

Accepted Answer

Nothing has been measured between them. No trial among the research behind this page has given semaglutide and retatrutide to the same participants, and retatrutide carries no approval for any use. What exists is a class-level description. A 2024 narrative review in Diabetes Care groups liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) as peptides with incretin agonist activity that induce around 15 to 24% weight loss in adults with overweight and obesity. That band covers four compounds at once and separates none of them. A range drawn across a whole class cannot be read as a ranking of any two members. A shared band is a statement about the class rather than about either compound, and the trial that would settle the pair is not one we could find.

Question 13

How does semaglutide compare with liraglutide?

Accepted Answer

They came out of the same design work, and what separates them is how long each one lasts. A 2019 review charts the discovery and development of the long-acting GLP-1 analogs liraglutide and, subsequently, semaglutide, and records that reversible binding to albumin was used for the systemic protraction of liraglutide and semaglutide. Protraction here means making a molecule last longer in the blood. The result is a daily injection on one side and a weekly one on the other. A 2021 review places liraglutide among the agents injected once daily (lixisenatide and liraglutide), and semaglutide among those given once a week. Both reached obesity by the same route as well. The 2019 review notes that significant weight loss, through an effect to reduce energy intake, led to the approval of liraglutide (3.0 mg) for obesity, an indication currently under investigation with semaglutide at the time of writing.

Question 14

How do the comparisons hold up outside a trial?

Accepted Answer

Routine care does not separate these two compounds the way a league table would. A 2025 review of real-world use reports frequent gastrointestinal disturbances in GLP-1RA users, as also observed in trials, without splitting that observation between the members of the class. The same review groups them rather than ranking them, describing substantial benefits in weight loss, most so the newest medications semaglutide and tirzepatide. That sentence puts the two together, which is not what a reader looking for a winner expects to find. One pooled analysis does separate them, on a measure the weight headlines hide. A 2025 network meta-analysis of twenty-two randomised trials found that tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass. That applies to both of them, in the same direction.

Semaglutide comparisons and stacks